Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0MQTIB
ADC Name
hL49_34_Tyr-ADC
Synonyms
hL49_34_Tyr ADC
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Melanoma [ICD11:2C30]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
hL49_34_Tyr
  Antibody Info 
Antigen Name
Melanotransferrin (MELTF)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
mp-dLAE-PABC
  Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 12 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Maximum inhibition efficiency (MIE) 
36
%
A-375 cells
Amelanotic melanoma
Maximum inhibition efficiency (MIE) 
74
%
IGR-37 cells
Melanoma
Maximum inhibition efficiency (MIE) 
76
%
SK-MEL-28 cells
Cutaneous melanoma
Maximum inhibition efficiency (MIE) 
85
%
COLO 853 cells
Cutaneous melanoma
Maximum inhibition efficiency (MIE) 
85
%
SK-MEL-5 cells
Cutaneous melanoma
Maximum inhibition efficiency (MIE) 
90
%
A2058 cells
Melanoma
Half Maximal Inhibitory Concentration (IC50) 
28
nM
SK-MEL-28 cells
Cutaneous melanoma
Half Maximal Inhibitory Concentration (IC50) 
60
nM
SK-MEL-5 cells
Cutaneous melanoma
Half Maximal Inhibitory Concentration (IC50) 
64
nM
COLO 853 cells
Cutaneous melanoma
Half Maximal Inhibitory Concentration (IC50) 
369
nM
A2058 cells
Melanoma
Half Maximal Inhibitory Concentration (IC50) 
678
nM
IGR-37 cells
Melanoma
Half Maximal Inhibitory Concentration (IC50) 
> 2000
nM
A-375 cells
Amelanotic melanoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 12 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 36.00% Low CD228 expression (CD228+)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Amelanotic melanoma A-375 cells CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 74.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma IGR-37 cells CVCL_2075
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 76.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-28 cells CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 85.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma COLO 853 cells CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 85.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 90.00% Moderate CD228 expression (CD228++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma A2058 cells CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 28.00 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-28 cells CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 60.00 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 64.00 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma COLO 853 cells CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 369 nM Moderate CD228 expression (CD228++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma A2058 cells CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 678 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma IGR-37 cells CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 2000 nM Low CD228 expression (CD228+)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Amelanotic melanoma A-375 cells CVCL_0132
References
Ref 1 Anti-cd228 antibodies and antibody-drug conjugates; 2022-02-10.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.